Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats

Abstract

Hypertension is one of the main causes of premature death in the world; also, it is associated with several bone alterations. Preclinical studies have demonstrated delayed alveolar bone healing in hypertensive rats. However, losartan has been favorable for consolidation of bone grafts and reduction in active periodontitis. Therefore, losartan is suggested to be effective in bone formation stages, as well as in the synthesis of matrix proteins and mineralization. Objectives: To evaluate the alveolar bone dynamics in hypertensive rats treated with losartan by laser confocal microscopy and histological analysis. Methodology: Thirty-two rats, 16 spontaneously hypertensive rats (SHR) and 16 Wistar albinus rats, treated or not with losartan (30 mg/kg/day) were used. Calcein fluorochrome at 21 days and alizarin red fluorochrome at 49 days were injected in rats (both 20 mg/kg). The animals were submitted to euthanasia 67 days after treatment, and then the right maxilla was removed for laser confocal microscopy analysis and the left maxilla for histological analysis. Results: This study showed a greater calcium marking in normotensive animals treated with losartan in relation to the other groups. Laser confocal microscopy parameters showed higher values of bone volume formed, mineralized surface, active surface of mineralization and bone formation rate in normotensive animals treated with losartan. However, a smaller mineralized surface was observed in all hypertensive animals. Conclusion: Losartan can improve bone mineralization parameters under normal physiological conditions, but the same anabolic effect does not occur under hypertension.

Keywords: Losartan. Spontaneously hypertensive rats. Bone. Hypertension.

Gabriel MULINARI-SANTOS
Jaqueline Silva dos SANTOS
Leticia Pitol PALIN
Ana Cláudia Ervolino da SILVA
Cristina ANTONIAL
Leonardo Perez FAVERANI
Roberta OKAMOTO

Submitted: October 10, 2018
Modification: March 2, 2019
Accepted: April 9, 2019

Corresponding address:
Gabriel Mulinari dos Santos - Departamento de Cirurgia e Clínica Integrada - Faculdade de Odontologia de Araçatuba - UNESP - Universidade Estadual Paulista - Departamento de Ciências Básicas, Faculdade de Odontologia de Araçatuba, Araçatuba, São Paulo, Brasil.
³Affiliated with Research productivity scholarship (Process:306389/2017-7)
1Universidade Estadual Paulista - UNESP. Departamento de Cirurgia e Clínica Integrada, Faculdade de Odontologia de Araçatuba, Araçatuba, São Paulo, Brasil.
2Universidade Estadual Paulista - UNESP. Departamento de Ciências Básicas, Faculdade de Odontologia de Araçatuba, Araçatuba, São Paulo, Brasil.
3Affiliated with Research productivity scholarship (Process:306389/2017-7)
Introduction

Hypertension is a chronic disease with the highest number of premature deaths and care assistance in the world.\textsuperscript{1,2} Its high prevalence reaches about one in three young adults in the world, and this number is estimated to increase.\textsuperscript{3} In addition to cardiovascular diseases, hypertension is associated with chronic renal failure, stroke, and bone abnormalities, such as: abnormal calcium metabolism,\textsuperscript{4} altered alveolar bone quality,\textsuperscript{5} delayed alveolar bone healing,\textsuperscript{6} bone density loss,\textsuperscript{7} increased risk of fractures\textsuperscript{8} and, consequently, osteoporosis.\textsuperscript{9} The question arises whether bone changes may be associated with the vasoconstriction present in hypertension.\textsuperscript{10} Thus, plasma calcium supply would be reduced, impairing alveolar bone mineralization. Finally, alveolar bone dynamics can interfere direct in the success of clinical procedures, such as: tooth extraction, consolidation of bone grafts and implant osseointegration.

Renin-angiotensin system inhibition is a target for hypertension control.\textsuperscript{11} Then, angiotensin II receptor blockers can prevent vasoconstriction and high blood pressure.\textsuperscript{12} In addition, angiotensin II enhances bone resorption by increasing RANKL and osteoclastic activation.\textsuperscript{6,13,14} Also, it has effects of osteoblastic lineage changing,\textsuperscript{15,16} by decreasing the expression of osteogenesis-related transcription factors via the AT1 receptor, such as Runx2, Msx2, and osteocalcin.\textsuperscript{15} Losartan, as an angiotensin II receptor blocker,\textsuperscript{17} has attracted interest not only for being a vasodilator, but also for its positive effects in bone metabolism.\textsuperscript{18,19} Preclinical studies have reported benefits of losartan on bone fracture healing and reduction in bone fracture risk.\textsuperscript{20} They also reported improved bone graft healing.\textsuperscript{10} In \textit{in vitro}\textsuperscript{18} and \textit{in vivo} studies,\textsuperscript{21} losartan significantly enhanced bone density by decreasing osteoclastogenesis and increasing osteoblastic activity. Therefore, a topic to be evaluated referred to how antihypertensive drugs interfere in alveolar bone dynamics.

The action of losartan in the renin-angiotensin system, and its consequent influence on bone metabolism, is widely studied.\textsuperscript{19,22,23} Animals presented decrease in periodontal bone loss\textsuperscript{22,23} and orthodontic movement\textsuperscript{19} by effect of losartan in OPG/RANKL system. Other studies indicate delay in alveolar bone healing\textsuperscript{6} and lower alveolar bone density in spontaneously hypertensive rats (SHR).\textsuperscript{24} Vasoconstriction, with a consequential reduction in plasma calcium supply, can be the reason of delayed and decreased bone mineralization in hypertension. In this aspect, the vasodilatory effect of losartan can support alveolar bone mineralization.\textsuperscript{10} This hypothesis was tested in a study evaluating alveolar bone dynamics in hypertension rats treated with losartan. Despite the high prevalence of hypertensive patients, alveolar bone dynamics in hypertension remains uncertain.

Therefore, this study aimed to evaluate the areas of calcium marked by fluorochromes and alveolar bone dynamics parameters in hypertensive rats treated with losartan, such as bone volume formed, mineralized surface, active surface of mineralization, calcein, bone formation rate, and mineral apposition rate.

Methodology

Study design and ethics

This study received a favorable opinion from the Animal Research Ethics Committee under number 00404-2016. All work has been developed according to the ARRIVE guidelines. A total of 32 adult (16-week) male rats, whose body weight ranged from 250 to 300 grams, were used; being 16 Wistar (Rattus novergicus albinus Wistar) and 16 SHRs. The animals were kept in cages in a stable temperature environment (22°C ± 2°C, light control cycle 12 light hours, 12 hours dark), balanced diet (Ração Mogiana Alimentos SA, Campinas, Brazil). The animals were divided into four groups according to the drug treatment: Wistar, Wistar losartan, SHR, and SHR losartan. Randomization sequence of groups was performed using a computer-generated list of Stata 9.0 (StataCorp, College Station, TX, USA).

Losartan treatment and systolic blood pressure

Losartan (Biosintetica, São Paulo, Brazil) was orally administered at a dose of 30 mg/kg daily until euthanasia.\textsuperscript{10} Animals in the untreated groups received only water in this period. The systolic blood pressure was measured every 7 days by tail-cuff indirect plethysmography using the Physiograph®, MK-III-S plethysmograph (Narco Bio-systems, Houston, Texas), performed according to previous studies.\textsuperscript{6,10} Losartan controlled all hypertensive animals’ blood pressure, without changes in the Wistar group treated.
Fluorochrome application

21 days after beginning drug treatment, the fluorochrome calcein was administered intramuscularly (20 mg/kg). Alizarin red fluorochrome was also used intramuscularly at a dose of 20 mg/kg for each animal after more 28 days, according to previous studies. The first injected calcein fluorochrome indicates calcium deposition in old bone and the subsequent alizarin fluorochrome in the newly-formed bone.

Euthanasia

All animals were submitted to euthanasia 67 days after drug treatment with an intravenously lethal excessive anesthetic dose (60 mg/kg, Tiopental Cristália Ltda; Itapira, SP, Brazil). Therefore, this experimental period is adequate to characterize the modeling or remodeling process of old bone into new bone indicated by fluorochromes and histology.

Laboratory processing

The right side of the maxilla was removed and fixed in 10% formaldehyde. After 48 hours, they were washed 24 hours in running water and dehydrated in an increasing alcohol sequence. The samples were soaked and infiltrated in a solution of acetone and methylmethacrylate MMAL (Classical, Dental Articles Classical, São Paulo, SP, Brazil) in ratio of 1:1, followed by methylmetracrylate baths. Benzoyl peroxide (1%, Riedel-de Haen AG, Seelze-Hannover, Germany) was added to the latter bath. Samples were placed in glass tubes and maintained at 37°C for 5 days. Resin blocks containing the samples were removed from the glass tubes after polymerization. The blocks were reduced to the maxilla sagittal plane. The reduction occurred with “Maxcut” drill mounted on an electric motor (Strong 210, São Paulo, SP, Brazil). Afterwards, the samples were submitted to a progressive wear on politriz (Ecomet 250 pro/automet 250, Buchler, Lake Bluff, Illinois) with sandpaper (120, 300, 400, 600, 800, and 1200 granules, Carbimet, Buchler, Lake Bluff, Illinois) under fluorescent light up to the thickness of 80 μm, conferred with digital caliper (Mitutoyo, Pompeia, São Paulo, Brazil). The sections obtained were mounted on slides immersed in mineral oil (Petrolato liquid, Maantecor, Taquara, Rio de Janeiro, Brazil) and fixed with enamel to prevent the oil from being trapped.

Laser Confocal Microscopy

The longitudinal scan of each maxilla was performed using Leica CTR 4000 CS SPE microscope (Leica Microsystems, Heidelberg, Germany), using a 10x objective (Original magnification of 100x). The area evaluated was the bone adjacent to the apical third of the right upper incisor. After selecting the thickness of the slices, images were reconstructed in microscope program (Leica CTR 4000 CS SPE, Leica Microsystems, Heidelberg, Germany). The blue filter was used to visualize the calcein fluorochrome, shown in green color (Figure 1A). The alizarin fluorochrome was revealed in red by green filter (Figure 1B).

Overlapping of the two layers of fluorochromes was performed, representing calcium deposition in both periods (Figure 1C). Therefore, this overlap shows the conversion of old bone into new bone. Images were saved in TIFF format and moved to the Image J program (Processing Software and Image Analysis, Ontario, Canada). Using the “color selection” tool, each image was standardized according to hue, saturation, and brightness. Both bone types were observed in the same setting on a single slide for measure the parameters: Bone volume formed,

Figure 1- Alveolar bone dynamics by confocal laser microscopy. Representative image of the biomarking of the fluorochromes in the alveolar bone of the maxilla estimated by "Color Selection" tool in the Image J program (Processing Software and Image Analysis, Ontario, Canada). A: Green biomarking of calcein fluorochrome. B: Red biomarking of the alizarin fluorochrome. C: Overlapping of both fluorochromes characterizing the alveolar bone dynamics.
mineralized surface, active surface of mineralization (alizarin fluorochrome), calcein, bone formation rate, and mineral apposition rate (MAR).

All parameters were estimated using the Image J program (Processing Software and Image Analysis, Ontario, Canada), using calcein fluorochrome initial values and the active mineralization surface, according to previous study.28 Mineral apposition rate was the daily value of mineralization, estimated by the distance between calcein and alizarin, divided by the 28 days among their administrations. The mineralized surface was estimated by dividing calcein and alizarin percentage by the total bone surface area. Bone volume formed was estimated by the multiplication of MAR by the mineralized surface and the total bone surface area.

Histological analysis

Later, the left hemi-maxilla was washed 24 hours in running water and decalcified in 10% EDTA for 6 weeks. They were washed for 24 h, dehydrated through an alcohol sequence, cleared in xylene and embedded in paraffin (Merck, Kenilworth, NJ, USA). 5-µm thick sections were cut with a microtome and mounted on glass slides. Alizarin red and Stevenel’s blue-stained slides were captured using a Nikon microscope (Eclipse 80i, Shinagawa, Tokyo, Japan). Bone tissue morphology was qualitatively evaluated, establishing comparison between the groups. The slides were photomicrographs magnified from the originals by 10x.

Statistical analysis

The GraphPad Prism 7.0 profiler (GraphPad Software, La Jolla, USA) was used for statistical test. Shapiro-Wilk test (p<0.05) was performed to verify homoscedasticity and whether the results were parametric. After confirming the normal distribution, Anova test was performed followed by Tukey post-test for multiple comparisons when necessary. For all tests, the p-value considered as significant was p<0.05.

Results

Systolic blood pressure and body weight

Figure 2A shows the systolic blood pressure along the experiment. Losartan controlled all hypertensive animals’ blood pressure. SHR obtained the highest systolic blood pressure mean values with statistical difference compared with SHR Losartan (171.4±0.6 versus 129.3±0.9 mmHg, p=0.04). There was no variation between Wistar and the Wistar group treated (105.1±1.1 versus 104.2±1.0 mmHg, p=0.14). Body weights mean in Figure 2B also showed no statistical difference (p>0.05), Wistar=294.1±1.9 grams, Wistar Losartan=289.4±1.5 grams, SHR=253.6±1.1 grams, and SHR Losartan=264.2±1.3 grams.

Qualitative analysis

Figure 3 shows the alveolar bone dynamics through the precipitation of fluorochromes in each group. The fluorochromes that bound to calcium at the time of their precipitation in organic bone matrix enabled the overlap between old (green) bone and new (red) bone. The first fluorochrome injected was calcein; therefore, it was the green biomarking of the old bone. Calcein biomarkers were present in all groups, with higher intensity in both Wistar groups and lowest in the SHR Losartan. The last injected fluorochrome was Alizarin, so the biomarking in red represented the newly-formed bone, which we call the active surface of mineralization. It was also present in all groups, being more intensive in the Losartan Wistar group and less evident in the SHR group.

Quantitative analysis

Bone volume formed

The highest bone volume formed occurred in Wistar Losartan with 65650572 µm³, showing statistical difference compared with all other groups (p<0.05; Figure 4A).

Mineralized surface

Wistar Losartan showed the highest percentage, with 15.34% of mineralized surface, showing statistical difference compared with the other groups (p<0.05, Figure 4B)

Active surface of mineralization

Wistar Losartan obtained the highest fluorochrome alizarina biomarking values, showing statistical difference with the Wistar (118235 versus 33189 µm², p=0.011), SHR (118235 versus 37351 µm², p=0.014), and no difference with the SHR group losartan (118235 versus 71638 µm²; p=0.1642) (Figure 4C).

Bone formation rate

The Wistar Losartan also revealed the highest
bone formation rate with 53.9 μm²/μm²/day, showing statistical difference compared with both hypertensive animal groups (p<0.05; Figure 4D).

Mineral apposition rate

SHR losartan showed higher daily mineral apposition rate compared with Wistar (16.01 versus 10.58 μm, p=0.0141) and SHR (16.01 versus 10.91 μm, p=0.014) and no difference with Wistar Losartan (16.01 versus 13.7 μm, p=0.361) (Figure 4E).

Calcein

The highest Calcein fluorochrome biomarker values were in Wistar, with statistical difference when compared with SHR (108578 versus 33052 μm²; p=0.0002) and SHR Losartan (108578 versus 50799 μm²; p<0.0001) (Figure 4F).

Histological analysis

Figure 5 provides an overview of the bone dynamics

Figure 2-Systolic blood pressure and body weight. Graph with the systolic blood pressure measured by tail-cuff indirect plethysmography using the Physiograph®, MK-III-S plethysmograph (Narco Bio-systems, Houston, Texas). The * indicates statistical difference of the SHR blood pressure group compared with the others (p<0.05). Additionally, the body weights were checked during the experiment and were similar between the groups treated with balanced diet (Ração Mogiana Alimentos SA, Campinas, Brazil)

Figure 3-Alveolar bone dynamics. Representative image of bone dynamics by overlapping the fluorochromes of calcein and alizarin in the alveolar bone of the maxilla in each group for Wistar, Wistar Losartan, SHR, and SHR Losartan using the Image J (Processing Software and Image Analysis, Ontario, Canada)
Losartan improves alveolar bone dynamics in normotensive rats but not in hypertensive rats

**Figure 4** - Parameters of laser confocal microscopy. Scatter-plots graphs with the confocal microscopy parameters evaluated in the alveolar bone of the maxilla. Data were obtained on 80 μm slides of the alveolar bone adjacent to the apical third of the right incisor. It was quantified: Calcein Fluorochromes, Active Mineralization Surface, Mineral apposition rate (MAR), Bone volume formed, Mineralized surface, and Bone formation rate. The * indicates significant statistical difference (p<0.05)

**Figure 5** - Histology of the maxilla. Histological images of the alveolar bone dynamics in the maxilla for Wistar, Wistar Losartan, SHR, and SHR Losartan. Presence of considerable bone was noted in the medullary compartment. All groups showed similar bone dynamics. Undecalcified thin-ground sections were prepared along the sagittal maxilla axis and Stevenel’s blue and red alizarin stained
Discussion

In addition to cardiovascular diseases, hypertension is associated with changes in bone metabolism. The renin-angiotensin system modulates inflammation in many conditions. Angiotensin II induces the activation of the extracellular-signal-regulated kinase pathway, having an upregulated RANKL expression, possibly enhancing bone resorption. This condition is able to decrease alveolar bone density and accelerate osteoporosis. Contrarily, antihypertensive drugs improve bone fracture healing and consolidation of bone grafts. Renin-angiotensin system interferes at vascular and cellular level in bone metabolism, thus the question arises whether alveolar bone mineralization could be impaired by hypertension. Furthermore, if losartan could improve mineralization by angiotensin II blocks, with consequent increase in calcium supply and osteoclastogenesis inhibition. Confirming this hypothesis, this study showed a positive effect of losartan on normotensive animals’ alveolar bone dynamics, but not in hypertensive model. Results showed a higher calcium marking in normotensive animals treated with losartan compared with that of other groups. In support of this result, laser confocal microscopy parameters showed high values of bone volume formed, mineralized surface, active surface of mineralization, and bone formation rate in normotensive animals treated with losartan. Results also showed lower mineralized surface in hypertensive animals.

Previous studies corroborate the favorable losartan effect in normotensive animals’ alveolar bone dynamics. One example is the improvement in bone graft consolidation in wistar rats treated with losartan. Other preclinical studies have shown decreased osteoclastogenesis by losartan, reducing the orthodontic movement and periodontal bone loss. Interestingly, in situations not related to hypertension, such as osteoporosis, this drug could increase bone mineral density in ovarectomized rats’ femurs. Also, other previous findings reveal an angiotensin II increase in hypertension, and its catabolic action on bone metabolism. Diversely, estrogen decreased angiotensin II levels. Thus, osteoprotective effect of losartan was confirmed in fractures of osteoporotic animals, in which losartan increased microcirculation and consolidation of bone fractures. Additional study reported the ability of losartan to enhance endothelial cell proliferation and to correct hypertensive patients’ arterial structure.

Regarding the clinical relevance of this study, we highlight the anabolic effect of losartan on bone metabolism in the homeostasis physiological condition. Our findings corroborate a greater mineral deposition in normotensive animals treated with losartan. Although bone dynamics involves a complex mechanism, we observed two crucial effects of losartan. First, its vasodilatory action possibly increased the plasma calcium supply, and, consequently, bone mineral deposition. Second, its performance on RANKL/OPG system can increase osteoblastic activity and reduce osteoclastogenesis, as validated in previous studies. For the clinical relevance, studies on the use of losartan to improve osseointegration in normotensive individuals or low bone density condition might be suggested. Also, regarding Implantology, the action of losartan on bone reconstruction with biomaterials can be analyzed to evaluate the occurrence of these benefits. In addition, in Periodontology, it must be investigated whether losartan can prevent or diminish periodontal bone loss. Corroborating our considerations, recent clinical studies showed antihypertensives as responsible for the increased success rate of osseointegrated dental implants. Another clinical study shows the reduction in fracture risk in hemodialysis patients treated with antihypertensive drugs. Additionally, a new study revealed the positive effect of losartan in impaired osseointegration of SHRs.
these results, the need for further studies of the clinical application of losartan is clear. No surgical procedure was performed in this experiment, thus bone dynamics under homeostasis conditions was evaluated, without the influence of a healing stimulus.

Regarding the limitations of this study, determining whether the action of losartan is effective for the improvement in bone dynamics at vascular or cellular level was not possible. Despite the several parameters analyzed, the interpretation of the results was performed considering two specific cellular analysis; extrapolating the results to bone mechanical behavior was not possible. The animal model used only partially reflects the clinical reality and the human bone metabolism. Also, this study did not consider nutritional factors, such as vitamin D and calcium intake levels, which may interfere in bone mineralization. Therefore, future studies should focus on determining how losartan can act on bone metabolism. Efforts should go beyond preclinical studies to check whether alveolar bone density is greater in subjects treated with losartan or other antihypertensives. Finally, future studies should distinguish in which physiological conditions losartan can reverse the inadequate bone metabolism.

In conclusion, losartan can improve bone mineralization in normal physiological conditions, but the same anabolic effect does not occur in hypertension.

Acknowledgments

The study was financially supported by the São Paulo Research Foundation (FAPESP) with process number 2016/03245-2, 2017/23082-3 and 2017/16912-0.

References

1- World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks; 2009.
2- Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75. doi: 10.1161/01.hyp.0000252676.46043.18
3- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23. doi: 10.1016/s0140-6736(05)17741-1
4- McCarron DA, Yung NN, Ugoretz BA, Krutzik S. Disturbances of calcium metabolism in the spontaneously hypertensive rat. Hypertension. 1981;3:1162-7.
5- Bastos MF, Brilhante FV, Goncalves TE, Pires AG, Napimoga MH, Marques MR, et al. Hypertension may affect tooth-supporting alveolar bone quality: a study in rats. J Periodontol. 2010;81:1075-83. doi: 10.1902/jop.2010.090705
6- Manrique Q, Pereira CC, Luvizuto ER, Sánchez MP, Okamoto T, Okamoto R, et al. Hypertension modifies OPG, RANK, and RANKL expression during the dental socket bone healing process in spontaneously hypertensive rats. Clin Oral Investig. 2015;19:1319-27. doi: 10.1007/s00078-014-1369-0
7- Afghani A, Goran MI. Lower bone mineral content in hypertensive compared with normotensive overweight Latino children and adolescents. Am J Hypertens. 2007;20:190-6. doi: 10.1016/j.amjhyper.2006.07.014
8- Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue Int. 2009;84:103-11. doi: 10.1007/s00223-008-9198-2
9- Vareena M, Manara M, Gali L, Binelli L, Zucchi F, Sinigaglia L. The association between osteoporosis and hypertension: the role of a low dairy intake. Calcif Tissue Int. 2013;93:86-92. doi: 10.1007/s00223-013-9731-9
10- Geall WC, Pereira CC, Luvizuto ER, García-Júñor IR, Antoniali C, Okamoto R. Healing process of autogenous bone graft in spontaneously hypertensive rats treated with losartan: an immunohistochemical and histomorphometric study. J Oral Maxillofac Surg. 2014;72:2569-81. doi: 10.1016/j.joms.2014.07.010
11- See S. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother. 2001;2:1795-804. doi: 10.1517/14656566.2.11.1795
12- Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA.. Losartan: comprehensive profile. Profiles drug subst expit relat methods. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003
13- Guo L, Wang M, Zhang ZY, Hao L, Lou BY, Li XY, et al. Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/2 pathway via AT1 receptor. Arch Oral Biol. 2011;56:205-11. doi: 10.1016/j.archoralbio.2010.09.016
14- Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. Fasebj. J. 2008;22:2465-75. doi: 10.1096/fj.07-098954
15- Nakai K, Kawato T, Morita T, Yamazaki Y, Tanaka H, Tonogi M, et al. Angiotensin II suppresses osteoblastic differentiation and mineralized nodule formation via AT1 receptor in ROS17/2.8 cells. Arch Oral Biol. 2015;11:628-37. doi: 10.5114/iosms.2015.52369
16- Nakai K, Kawato T, Morita T, Inuma T, Kamio N, Zhao N, et al. Angiotensin II induces the production of MMP-3 and MMP-13 through the MAPK signaling pathways via the AT(1) receptor in ROS17/2.8 cells. Arch Med Sci. 2010;6:102-13. doi: 10.5114/ams.2010.105019
17- Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA.. Losartan: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003
18- Chen S, Grover M, Sibai T, Black J, Rianon N, Rajagopal A. Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. Mol Genet Metab. 2015;115:53-60. doi: 10.1016/j.migm.2015.02.006
19- Moura AR, Montalvany-Antonacci CC, Taddei SR, Queiroz-Junior CM, Okamoto R, et al. Hypertension modifies OPG, RANK, and RANKL expression during the dental socket bone healing process in spontaneously hypertensive rats. Clin Oral Investig. 2015;19:1319-27. doi: 10.1007/s00078-014-1369-0
20- Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa MU, et al. Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One. 2015;10:e0122691. doi: 10.1371/journal.pone.0122691
21- Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep. 2012;64:878-88.
22- Santos CF, Morandini AC, Dionisio TJ, Faria FA, Lima MC, Figueiredo CM, et al. Functional local renin-angiotensin system in human and rat periodontal tissue. PLoS One. 2015;10:e0134601. doi: 10.1371/journal.pone.0134601

23- Queiroz-Junior CM, Silveria KD, Oliveira CR, Moura AP, Madeira MF, Sorani FM, et al. Protective effects of the angiotensin type 1 receptor antagonist losartan in infection-induced and arthritis-associated alveolar bone loss. J Periodontal Res. 2015;50:814-23. doi: 10.1111/jre.12269

24- Manrique N, Pereira CC, Garcia LM, Micaroni S, Carvalho AA, Perri SH, et al. Alveolar bone healing process in spontaneously hypertensive rats (SHR). A radiographic densitometry study. J Appl Oral Sci. 2012;20:222-7.

25- Faverani LP, Polo TO, Ramalho-Ferreira G, Momesso GAC, Hassumi JS, Rossi AC, et al. Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. Clin Oral Investig. 2018;22(1):255-65. doi: 10.1007/s00784-017-2106-2

26- Ramalho-Ferreira G, Faverani LP, Grossi-Oliveira GA, Okamoto T, Okamoto R. Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis. J Biomed Opt. 2015;20:038003. doi: 10.1117/1.1803080

27- Ramalho-Ferreira G, Faverani LP, Prado FB, Garcia IR Jr, Okamoto R. Raloxifene enhances peri-implant bone healing in osteoporotic rats. Int J Oral Maxillofac Surg. 2015;44:798-805. doi: 10.1016/j.ijom.2015.02.018

28- Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28:2-17. doi: 10.1002/jbmr.1805

29- Cappuccio FR, Kalaizidis R, Dunclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol. 2000;13:169-77.

30- Javed F, Khan SA, Ayers EW, Aziz EF, Akram MS, Nkadarni GN, et al. Association of hypertension and bone mineral density in an elderly African American female population. J Natl Med Assoc. 2012;104:172-8.

31- Yamamoto S, Kido R, Onishi Y, Fukushima S, Akizawa T, Fukagawa M, et al. Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One. 2015;10:e0122691. doi: 10.1371/journal.pone.0122691

32- Rajkumar DS, Faitelson AV, Gudyrev OS, Dubrovin GM, Pokrovski MV, Ivanov AV. Comparative evaluation of enalapril and losartan in pharmacological correction of experimental osteoporosis and fractures of its background. J Osteoporos. 2013;2013:325693. doi: 10.1155/2013/325693

33- Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, et al. Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension. 2002;40:451-7; discussion 448-50.

34- Suzuki R, Fukuda N, Katakawa M, Tsunemi A, Tahira Y, Matsumoto T, et al. Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. Am J Hypertens. 2014;27:695-701. doi: 10.1093/ajh/hpt208

35- Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653-9.

36- Wu X, Al-Abedalla K, Emir H, Arekunamath Madathill S, Abi-Nader S, Daniel NG et al. Antihypertensive medications and the survival rate of osseointegrated dental implants: a cohort study. Clin Implant Dent Relat Res. 2016;18:1171-82. doi: 10.1111/cid.12414

37- Garcia-Denche JT, Wu X, Martinez PP, Emir H, Ikbal DJ, Hernandez G, et al. Membranes over the lateral window in sinus augmentation procedures: a two-arm and split-mouth randomized clinical trials. J Clin Periodontol. 2013;40:1043-51. doi: 10.1111/jcpe.12153

38- Mulinari-Santos G, Souza Batista FR, Kirchweger F, Tangi S, Gruber R, Okamoto R. Losartan reverses impaired osseointegration in spontaneously hypertensive rats. Clin Oral Implants Res. 2018 Sep 28. doi: 10.1111/ciir.13376